Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Rejigs Executives, New Chief For North America Business

Executive Summary

Ex-Torrent COO Arunesh Verma to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.

You may also be interested in...



More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business

Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”

Sandoz Will Not Pursue US Advair Rival

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141586

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel